What “Complete Remission” Means in a New Kidney-Treatment Approval
FDA’s obinutuzumab decision rests on a specific measure of proteinuria remission. That endpoint deserves explanation alongside the treatment’s risks.
By Maya Bell · November 17, 2026 · 2 min read